A5014359822- Lipoproteins and Cardiovascular Health
- Peroxisome Proliferator-Activated Receptors
- Cancer, Lipids, and Metabolism
- Fatigue and fracture mechanics
- Diabetes Treatment and Management
- Welding Techniques and Residual Stresses
- Surface Roughness and Optical Measurements
- Photosynthetic Processes and Mechanisms
- Liver Disease Diagnosis and Treatment
- Lipid metabolism and disorders
- Non-Destructive Testing Techniques
- Algal biology and biofuel production
- Nuclear Receptors and Signaling
- Advanced machining processes and optimization
- Meta-analysis and systematic reviews
- Parasitic Diseases Research and Treatment
- Biomedical Research and Pathophysiology
- Microbial Community Ecology and Physiology
- Hydrogen embrittlement and corrosion behaviors in metals
- Diet and metabolism studies
- Advanced Surface Polishing Techniques
- Liver Diseases and Immunity
- Ethics in Clinical Research
- Dermatological diseases and infestations
- Surface Treatment and Residual Stress
Kowa (Japan)
2021-2025
Saga University
2024-2025
Kumamoto University
2017-2018
Tokyo Institute of Technology
2014
The University of Tokyo
2002-2003
Nagoya University
2002
Summary Background Pemafibrate is a novel, selective peroxisome proliferator‐activated receptor α modulator (SPPARMα). In mice, improved the histological features of non‐alcoholic steatohepatitis (NASH). patients with dyslipidaemia, it serum alanine aminotransferase (ALT). Aims To evaluate efficacy and safety in high‐risk, fatty liver disease (NAFLD). Methods This double‐blind, placebo‐controlled, randomised multicentre, phase 2 trial 118 (1:1) to either 0.2 mg or placebo, orally, twice...
The transcription factor NtcA is a global regulator of nitrogen homeostasis in cyanobacteria. It thus positively regulates the expression genes related to assimilation such as glnA (which encodes glutamine synthetase) and ntcA itself response shortage or depletion. binding promoters Synechococcus sp. PCC 7942 vitro now has been shown be enhanced by 2-oxoglutarate. In analysis gene also revealed that interaction with its promoter element was not sufficient for activation transcription,...
Aims: Pemafibrate, a selective peroxisome proliferator-activated receptor α modulator that lowers serum triglyceride levels and increases high-density lipoprotein cholesterol levels, is approved for treating dyslipidemia as twice-daily immediate-release (IR) tablets. A once-daily extended-release (XR) tablet has also been developed. We aimed to confirm the non-inferiority of XR (0.2 or 0.4 mg/day; once daily) IR twice in lowering patients with hypertriglyceridemia.
Long-term safety and efficacy of pemafibrate once-daily extended-release (XR) tablets, taken in morning or evening, were evaluated dyslipidemic patients with high triglycerides (TG). In this multicenter, randomized, open-label, parallel-group, phase 3 long-term study, TG randomly assigned to evening administration XR for 52 weeks. The dose was started at 0.2 mg/day increased 0.4 having fasting serum ≥ 150mg/dL during treatment. primary endpoint percent change TG. study enrolled 121 patients,...
ABSTRACT Background Pemafibrate, a selective peroxisome proliferator‐activated receptor alpha (PPARα) modulator (SPPARMα), has positive effects on liver‐related markers (e.g., liver stiffness determined by magnetic resonance elastography and alanine aminotransferase) in the PEMA‐FL study patients with metabolic dysfunction‐associated steatotic disease (MASLD). Patients MASLD reportedly have high rate of muscle mass loss; hence, prevention treatment sarcopenia is important for MASLD. PPARα...
Abstract Elevated triglyceride levels are associated with an increased risk of cardiovascular events despite guideline‐based statin treatment low‐density lipoprotein cholesterol. Peroxisome proliferator‐activated receptor α (PPARα) agonists exert a significant triglyceride‐lowering effect. However, combination therapy PPARα statins poses rhabdomyolysis, which is rare but major concern the therapy. Pharmacokinetic interaction suspected to be contributing factor risk. To examine potential for...
Pemafibrate substantially lowers serum triglyceride (TG) levels and increases high-density lipoprotein cholesterol (HDL-C) primarily in Japan, but it has not been evaluated China. We aimed to confirm the efficacy safety of pemafibrate Chinese patients with hypertriglyceridemia low HDL-C by comparing placebo fenofibrate. A multicenter, double-masked trial was conducted China involving 344 high TG randomly assigned one four groups: 0.2 mg/d, 0.4 fenofibrate 200 or for 12 weeks. The primary...
The levels of transcripts the cpc operon were highly reduced in a PD-1 mutant cyanobacterium Synechocystis sp. strain PCC 6714. This was due to substitution C for T that occurred at 5 bp upstream transcription initiation site operon. Any -5 position drastically both vivo and vitro promoter activity Synechococcus 7942 but not Escherichia coli. suggests requirement -5T appears be specific cyanobacterial RNA polymerase-promoter combination.
We compared the efficacy and safety of pitavastatin/ezetimibe fixed-dose combination with those pitavastatin monotherapy in patients hypercholesterolemia.
Efficacy, safety, and pharmacokinetics of the selective PPARα modulator pemafibrate as once-daily extended-release (XR) tablets were compared with those twice-daily immediate-release (IR) in patients hypertriglyceridemia.
In the PEMA-FL study in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), pemafibrate was shown to significantly decrease low-density lipoprotein cholesterol (LDL-C) levels. We aimed investigate mechanisms of pemafibrate-induced LDL-C reduction MASLD by conducting an additional sub-analysis study.
Abstract Background Risk-based monitoring (RBM) is a slow uptake in some trial sponsors. There are three main reasons for this. First, there the fear of making large investments into advanced RBM technology solutions. Second, it considered that most suitable large, complex trials. Third, errors both critical and non-critical data, appearing as reduced on-site being conducted. Methods Our team identified, evaluated, mitigated risks, well devised strategy. The clinical research associate (CRA)...
Aim: Ezetimibe administration with ongoing statin therapy is an effective option for further lowering low-density lipoprotein cholesterol (LDL-C) levels. Thus, we investigated the long-term efficacy and safety of fixed-dose combination pitavastatin/ezetimibe (K-924 LD: 2 mg/10 mg; K-924 HD: 4 mg).
Stress corrosion cracking in nuclear power plants can be prevented by the shot peening process which gives compressive residual stress to surface of components. Therefore, it is important evaluate distribution near However, concerned that induced may decrease during long term operation. For this reason, necessary know actual after After East Japan Earthquake, several were decided decommissioned. By measuring on decommissioning components, possible change effect due There are some techniques...
Stress corrosion cracking in nuclear power plants can be prevented by the shot peening process which gives compressive residual stress to surface of components. Therefore, it is important evaluate distribution near However, concerned that induced may decrease during long term operation. For this reason, necessary know actual after After East Japan Earthquake, several were decided decommissioned. By measuring on decommissioning components, possible change effect due There are some techniques...